Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Cancer Research Communications|April 28, 2026
Cyclin-dependent kinase-9 and oxidative phosphorylation inhibition overcome ibrutinib resistance in mantle cell lymphomaCarly Roleder, Xiaofan Zhao, Vi Lam, et al.
American Journal of Hematology|October 18, 2019
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphomaAlex F Herrera, Andre Goy, Amitkumar Mehta, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2025
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma ConferenceAlexey V Danilov, Craig Sauter, Tycel Phillips, et al.
Journal of Hematology & Oncology|November 4, 2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)Michael Wang, Stephen J Schuster, Tycel Phillips, et al.
American Journal of Clinical Pathology|June 29, 2026
CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myelomaV Rakesh Sethapati, Vu Ngo, Alexey Danilov, et al.
Leukemia & Lymphoma|January 19, 2026
Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)Tycel Phillips, Ziqi Zhou, Cynthia Gutierrez, et al.
Molecular Cancer Therapeutics|July 7, 2023
T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic LeukemiaVi Lam, Carly Roleder, Tingting Liu, et al.
Leukemia & Lymphoma|April 15, 2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphomaWyndham H Wilson, Tycel Phillips, Leslie Popplewell, et al.
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Oncotarget|February 1, 2018
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomasCarlos Murga-Zamalloa, Avery Polk, Walter Hanel, et al.
Pageof 6